Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 38, 2012, Pages 15419-15424

  Xiao, Gang ^a   Deng, Anqi ^a   Liu, Haifeng ^a   Ge, Gaoxiang ^a   Liu, Xiaolong ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Antitumor immunity; T cell response; Transactivation

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE; TRANSACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; UPREGULATION;

ANIMALS; BINDING SITES; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE DELETION; MICE; MICE, INBRED C57BL; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-FOS; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION;

EID: 84866559149     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1206370109     Document Type: Article

References (35)

1. Kang T-W, et al. (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479:547-551.
2. Koebel CM, et al. (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903-907. (Pubitemid 350231320)
3. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999-1005. (Pubitemid 35363649)
4. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271.
5. Chiu R, et al. (1988) The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell 54:541-552.
6. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-E136. (Pubitemid 34521026)
7. Clark CE, Hasan M, Bousso P (2011) A role for the immediate early gene product c-fos in imprinting T cells with short-term memory for signal summation. PLoS ONE 6:e18916.
8. Ullman KS, Northrop JP, Verweij CL, Crabtree GR (1990) Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: The missing link. Annu Rev Immunol 8:421-452. (Pubitemid 20135634)
9. Macián F, López-Rodríguez C, Rao A (2001) Partners in transcription: NFAT and AP-1. Oncogene 20:2476-2489. (Pubitemid 32531304)
10. Ilkovitch D, Lopez DM (2009) The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 69:5514-5521.
11. Hahne M, et al. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274:1363-1366. (Pubitemid 26391458)
12. Fleischmann A, et al. (2003) Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J Neurosci 23: 9116-9122. (Pubitemid 37243812)
13. Mempel TR, Henrickson SE, Von Andrian UH (2004) T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427:154-159. (Pubitemid 38094955)
14. Martin-Orozco N, et al. (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787-798.
15. Wang X, Zhang Y, Xiao G, Gao X, Liu X (2009) c-Fos enhances the survival of thymocytes during positive selection by upregulating Bcl-2. Cell Res 19:340-347.
16. Willimsky G, Blankenstein T (2005) Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141-146. (Pubitemid 41613441)
17. Ahmadzadeh M, et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-1544.
18. Oestreich KJ, Yoon H, Ahmed R, Boss JM (2008) NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 181:4832-4839.
19. Terawaki S, et al. (2011) IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 186: 2772-2779.
20. Curiel TJ, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949. (Pubitemid 39273735)
21. Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 12:954-961.
22. Ray N, et al. (2006) c-Fos suppresses systemic inflammatory response to endotoxin. Int Immunol 18:671-677. (Pubitemid 43779057)
23. Koga K, et al. (2009) Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 30: 372-383.
24. Rosette C, Karin M (1996) Ultraviolet light and osmotic stress: Activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274: 1194-1197. (Pubitemid 26389285)
25. Schaeuble K, Hauser MA, Singer E, Groettrup M, Legler DF (2011) Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. J Immunol 187:5645-5652.
26. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704. (Pubitemid 351600389)
27. Okazaki T, et al. (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477-1483. (Pubitemid 38004774)
28. Prokunina L, et al. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666-669. (Pubitemid 35435182)
29. Day CL, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354. (Pubitemid 44435155)
30. Chemnitz JM, et al. (2007) RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. Blood 110:3226-3233. (Pubitemid 350106315)
31. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7:95-106. (Pubitemid 46160986)
32. Kao C, et al. (2011) Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 12:663-671.
33. Goldberg MV, et al. (2007) Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 110:186-192. (Pubitemid 47026834)
34. Francisco LM, et al. (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015-3029.
35. Curotto de Lafaille MA, et al. (2001) Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes. J Exp Med 194:1349-1359.